Autolus targets 60+ authorized centers by year-end 2025 while signaling expanded U.S. AUCATZYL access
Source: SeekingAlpha
2025-08-12 16:38:50 ET
More on Autolus Therapeutics
- Autolus Therapeutics plc (AUTL) Q2 2025 Earnings Call Transcript
- Autolus Therapeutics plc 2025 Q2 - Results - Earnings Call Presentation
- Autolus: A Buy Before Key Data Readout, Potential Expansion Into Autoimmune Market
- Autolus Therapeutics Q2 2025 Earnings Preview
- SA Asks: Which oncology companies are attractive M&A targets?
Read the full article on Seeking Alpha
For further details see:
Autolus targets 60+ authorized centers by year-end 2025 while signaling expanded U.S. AUCATZYL access
Autolus Therapeutics plc
NASDAQ: AUTL
AUTL Trading
22.54% G/L:
$1.93 Last:
4,124,476 Volume:
$1.62 Open:
AUTL Latest News
May 14, 2026 07:00:00 am
Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business UpdatesMay 05, 2026 07:00:00 am
Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026April 29, 2026 04:05:00 pm
Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost ReductionAUTL Stock Data
$387,238,481
109,839,996
N/A
49
N/A
Biotechnology & Life Sciences
Healthcare
GB
London
